Teva Pharmaceutical Industries Limited, a global pharmaceutical company, engages in the development, production and marketing of generic drugs covering major treatment categories. The company also has a pharmaceutical business, whose primary products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease, as well as a proprietary specialty business, which consists primarily of respiratory products.
The company’s active pharmaceutical ingredient (API) business sells to third-party manufacturers. It also has an animal health business, with primary operations in the U.S., covering both the companion animal and economic animal markets.
The company's global operations are conducted throughout North America, Europe, Latin America, Asia and Israel. It has direct operations in approximately 50 countries, as well as 36 pharmaceutical manufacturing sites in 16 countries, 17 generic R&D centers operating within certain manufacturing sites and 18 API manufacturing sites around the world.
PHARMACEUTICAL PRODUCTS
Generic Products: Generic drugs are the chemical and therapeutic equivalents of brand-name drugs and are typically sold under their generic chemical names.
North America
Teva Pharmaceuticals USA, Inc. (Teva USA), the company’s primary U.S. subsidiary, is a generic drug company in the United States. Teva USA markets approximately 315 generic products in approximately 1,079 dosage strengths and packaging sizes in the U.S. Teva USA has the capability to formulate, fill, label and package finished dosage forms of injectable pharmaceutical products, which are sold in the U.S. Its customers include drugstore chains, wholesaling organizations, buying groups and managed care providers.
Through Novopharm Limited, the company manufactures and markets generic prescription drugs in Canada. Novopharm is a generic drug company in Canada and portfolio includes 170 generic products, which are sold in approximately 700 dosage forms and packaging sizes.
Products: Teva USA manufactures and sells various types of generic pharmaceutical products in various dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and, through the acquisition of Ivax Corporation (Ivax), inhalants. The four significant products that the company sold during 2006 under exclusivity in the U.S. were the generic versions of: Zocor (simvastatin), Zoloft (sertraline), Wellbutrin XL (bupropion) and Pravachol (pravastatin). In addition, during 2006, the company sold generic versions of the following branded products in the U.S.: DDAVP (desmopressin acetate), Clozaril (clozapine), Desferal (deferoxamine mesylate), Zonegran (zonisamide), Novantrone (mitoxantrone), MiraLax (polyethylene glycol), Proscar (finasteride), Mobic (meloxicam), Effexor (venlafaxine), Cipro (ciprofloxacin), Depo-Medrol (methylprednisolone acetate), Ditropan XL (oxybutynin), and Zofran (ondansetron). In 2006, Teva USA received 28 final generic drug approvals and 15 tentative approvals. The 15 tentative approvals received were for generic equivalents of the following products: Depakote, Actos, AdenoScan, Aciphex, Zofran (tablets and OD tablets), Sarafem, Protonix, Cozaar, Hyzaar, Lotrel, Risperdal, Avelox, Focalin and Wellbutrin XL (150 mg.).
During 2006, Novopharm launched 15 generic equivalents of the following brand products: Amaryl, Casodex, Effexor XR, Fludara, Imitrex DF, Lipidil Supra, Mirapex, Novatrone, Remeron RD, Risperidal, Serc, Tiazac, Zofran, Zofran Injectable and Zovirax.
Collaborations: The company and Biovail Corporation International, through subsidiaries, entered into a ten-year marketing and product development agreement that provided the company with U.S. marketing rights for certain of Biovail’s pipeline of controlled-release generic versions of successful brands. The products marketed by Teva USA under this arrangement are generic versions of Trental, Cardizem CD, Adalat CC, Procardia XL and Voltaren XR.
This agreement with Biovail was extended in 2004 by an additional four-year period. Under the 2004 amendment, Biovail also transferred all development and intellectual property rights for two additional extended-release generic products, which Teva has the right to develop and manufacture. Teva and Biovail have also entered into a long-term API supply agreement.
The company has entered into a strategic alliance agreement for twelve controlled-release generic pharmaceutical products with Impax Laboratories, Inc. The agreement grants the company U.S. marketing rights and an option to acquire marketing rights in the rest of North America, Latin America, the EU and Israel. Teva subsequently exercised its option with respect to the marketing rights of certain products in Canada.
The products subject to the agreement include the following products as to which Impax had pending abbreviated new drug applications (ANDAs) at the FDA and for which it has received final or tentative approval: generic versions of Claritin D12, Claritin D24, Claritin Reditabs, Wellbutrin SR tablets, Zyban tablets, Prilosec capsules, Ditropan XL and Allegra D12H. During 2004, generic versions of Wellbutrin SR tablets, Zyban tablets and Prilosec capsules were launched, and a generic version of Ditropan XL was launched in 2006.
In 2006, the company entered into an agreement with Impax and Anchen Pharmaceuticals, Inc. for the marketing of the generic version of Wellbutrin XL (bupropion) tablets, 300 mg, the branded product marketed by GlaxoSmithKline. Pursuant to its 2001 agreement with Impax, the company has U.S. marketing rights to Impax’s version of this product, and commenced sales in December 2006.
The company participates in a U.S. distribution arrangement with Baxter Healthcare Corporation for propofol, the generic version of Diprivan. Under the agreement, the company produces the product and sells it to Baxter, which then performs marketing and distribution functions related to the product.
In June 2005, the company entered into a strategic alliance arrangement with Barr Pharmaceuticals, Inc. for the marketing rights in the U.S. for the generic version of Allegra (fexofenadine) tablets. Under the agreement, Barr enabled Teva to launch its own product. The generic version of Allegra was launched in September 2005.
Marketing and Sales: During 2006, the company’s sales in the U.S. were made to drug store chains, drug wholesalers, mail order pharmacies, generic distributors, hospitals and affiliated organizations and others, including governmental institutions and managed care institutions. In Canada, Novopharm markets generic products to wholesalers and retail chains reaching approximately 7,500 pharmacies. Novopharm also has a hospital sales division, which offers 50 injectable products and covers approximately 900 hospitals throughout Canada.
Europe
The company is a generic pharmaceutical company in Europe with operations in 17 Western European countries, including Hungary. In 2006, the significant products sold by Teva in Europe were the generic versions of Zocor, Prezal, Zoloft, Taxol, Zofran, Imigran, Selektine, Zithromax, Lamictal, Zoton, Seroxat/Deroxat, Staril/Fosinopril and Fosamax Once Weekly. During 2006, Teva received 300 generic approvals, corresponding to 27 new compounds in 36 formulations. In addition, in Europe, as of December 31, 2006, Teva had approximately 1,800 marketing authorization applications pending approval corresponding to 140 compounds in 295 formulations. The company is a generic pharmaceutical company in the United Kingdom, The Netherlands and Italy.
Operations in Selected European Countries
The United Kingdom: In 2006, the company in the United Kingdom launched approximately 20 new products, such as the generic versions of Flomax, Ikorel and Imigran.
The Netherlands: During 2006, the company launched the generic versions of Flixonase, Imigran, Zofran and Zithromax. In addition, during 2006, Teva integrated Ivax’s marketing and sales activities in The Netherlands and launched branded products, such as Almogran, Orfiril (neurology segment), Qvar, Ipraxa, Ipramol, Airomir and Autohaler (asthma/COPD segment).
Hungary: In Hungary, the company operates as a supplier to hospitals, a supplier in the over-the-counter pharmaceutical market and a wholesaler. Its products include generic versions of Lipitor; Fosamax; Lanson and Alpha D3 (bone metabolism product).
France: In 2006, the company’s French subsidiary launched various significant products, including the generic equivalents of Taxol (a product acquired as part of the Ivax acquisition), Vastin /Elisor, Triatec and Zithromax. As a result of the integration of Ivax, Teva also entered into the branded respiratory market in France.
Italy: In 2006, the company launched generic versions of Augmentin, Claforan, Lansox, Omnic, Taxol, Fosamax and Flixonase.
Germany: The company maintains a limited presence in the German market, active mainly in the niche therapeutic areas of urology, oncology, nephrology and respiratory, as well as osteoporosis.
Spain: The company is in the early stages of development in the Spain market and has launched approximately 35 products targeted both to hospitals and pharmacies.
Other Western European Markets: The company also operates on a smaller scale in other Western European markets, such as Sweden, Finland, Denmark, Norway, Belgium, Switzerland, Ireland, Portugal, Austria and Greece.
International
The company's International Division is responsible for countries outside of the U.S., Canada and Western Europe. It operates internationally in Latin America, Israel, Central and Eastern Europe (CEE) and other countries.
Latin America
The company sells a portfolio of branded generic, non-branded generic and over-the-counter pharmaceutical products in Latin America. Mexico, Chile, Brazil, Argentina and Venezuela are the major markets in the region. Its operations in Brazil focus on Copaxone sales as well as oncology products. Teva has manufacturing operations in Mexico, Chile, Argentina, Peru and Venezuela and distributes its products throughout majority of Latin America.
Operations in Selected Latin American Countries
In Mexico, the company’s operations include four pharmaceutical manufacturing sites. Sales are made primarily to the public sector (through government tenders and institutional sales), while private sales, including sales of products and over-the-counter products, and exports to various other Latin American countries.
In Argentina, the company manufactures and sells approximately 170 branded generic and over-the-counter products. Sales are made primarily to distributors and wholesalers, with the remainder directly to healthcare institutions.
In Venezuela, the company’s primary business consists of branded generics, which are sold to distributors and wholesalers, with a portion of sales being made directly to pharmacies, institutions and governmental customers.
In Chile, the company’s subsidiary is a pharmaceutical company. Teva distributes its products to retail and institutional (hospitals and clinics) customers, and exports to thirteen other countries within the region.
In Peru, Teva’s operations include the pharmacy chain, as well as the pharmaceutical company in Peru.
Central and Eastern Europe (CEE)
The CEE region covers 23 countries. The company's main CEE markets are Russia, Poland and the Czech Republic. The Ivax acquisition expanded Teva’s CEE operations and provided Teva with a portfolio of generic prescription medications as well as over-the-counter drugs, vitamin supplements and medical devices. Sales in the region are made through subsidiaries, local representative offices and distributors in the different markets. In Russia, Poland, the Czech Republic, Slovakia, Romania, Bulgaria and Ukraine, Teva markets and sells branded non-proprietary pharmaceutical products.
In 2006, the key products sold by the company in the CEE were the generic versions of Novo-Passit, Beclazone, Simgal, Sanorin, Stoptussin, Stopangin, Alendronate and Equoral. In 2006, Teva received 261 generic approvals, corresponding to 64 new compounds in 72 formulations and 136 strengths. In addition, in the CEE, as of February 1, 2007, Teva had 430 marketing authorizations applications pending approval, corresponding to 65 molecules in 66 forms and 140 strengths.
Israel
The company is a non-governmental supplier of healthcare products and services in Israel. In this market, Teva is involved in the marketing, promotion, selling and distribution of a range of healthcare products and services. These include pharmaceutical products, generics, over-the-counter and consumer healthcare products, hospital supplies, dialysis equipment and disposables, diagnostics and home care services. The company supplies healthcare services for the geriatric market. In Israel, the company’s main customers include healthcare funds, hospitals, private pharmacies and pharmacy chains. Sales of Teva’s products in Israel are made through its distribution company, Salomon, Levin and Elstein, Ltd., which sells directly to institutional customers, as well as to the private pharmacies and chains.
Other Countries
China: In China, the company is engaged in initial efforts to capture a share of this market. Teva’s presence in China is based on assets acquired as part of the Sicor Inc. (Sicor) and Ivax acquisitions. In 2006, Teva increased its holdings in Tianjin Hualida Biotechnology Company, Ltd. to 60%. Hualida’s main product is Interferon Alpha 2B, used in the treatment of hepatitis and certain types of cancer and which is marketed in China. As part of the acquisition of Ivax, Teva acquired additional assets in China, including a 50% interest in Sino-American Kunming Baker Norton Pharmaceutical Co., Ltd., which produces and markets amoxicillin and cephaclor in China, as well as Teva’s Alpha D3 and other imported products.
SPECIALTY PHARMACEUTICAL PRODUCTS
The company's specialty pharmaceutical products business is focused on respiratory, bio-generics and biopharmaceutical products, as well as hospitals and institutional franchises.
Respiratory Products
Through the Ivax acquisition, the company involves in the development, manufacture and marketing (mainly in the United States and Europe) of inhaled respiratory drugs, primarily for bronchial asthma and chronic obstructive pulmonary disease, delivered by metered-dose and dry powder inhalers. The respiratory franchise includes various patented delivery systems, including Easi-Breathe, an advanced breath-activated inhaler (BAI), Spiromax/Airmax, a multi-dose dry powder inhaler and Cyclohaler, a single dose dry powder device. In addition, Teva markets various press and breathe metered dose inhalers as well as Steri-Nebs ampoules.
The company's primary branded respiratory products in the U.S. include ProAir (albuterol HFA), a short-acting beta agonist for treatment of bronchial spasms linked to asthma or chronic obstructive pulmonary disease, and exercise-induced bronchospasm, and QVAR (beclomethasone diproprionate HFA), an inhaled corticosteroid for long-term control of chronic bronchial asthma, which is manufactured by 3M Corporation pursuant to an agreement with Ivax. These products are marketed directly to physicians, pharmacies, hospitals, managed healthcare organizations and government agencies. Teva is also seeking approval for ProAir HFA Breath Actuated Inhalation Aerosol, based on the Easi-Breathe technology.
In Western Europe, the company’s respiratory franchise is developed in the United Kingdom, The Netherlands and France, mainly through the sale of salbutamol, beclomethasone in metered dose inhalers, QVAR and Airomir in metered dose inhalers and in Autohaler, as well as through QVAR, beclomethasone and salbutamol in Easi-Breathe , the Cyclohaler franchise, Budesonide in Spiromax/Airmax and various products in Steri-Nebs.
In the CEE, the emphasis is on Spiromax/Airmax (with budesonide), as an alternative to the multi-dose dry powder inhalers. The introduction of fluticasone nasal spray and Steri-Nebs is also planned across the region in 2007.
Biogenerics and Biopharmaceutical Operations
During 2006, the company marketed a portfolio of biopharmaceutical products, including interferon alpha 2b, granulocyte colony-stimulating factor and pursuant to an agreement with Savient, human growth hormone (hGH). Teva’s finished dosage biopharmaceutical manufacturing facilities are located in Mexico, Hungary and China (through Tianjin Hualida Biotechnology Company Ltd., of which Teva increased its holdings from 45% to 60% during 2006). Teva’s bulk substance manufacturing facilities are located in Lithuania and China.
In 2006, the company entered into two agreements related to the development of biopharmaceutical products: A collaboration and licensing agreement with Protalix, Ltd. for the development of two proteins, using Protalix’s plant cell culture platform. Under this agreement, the two companies would collaborate on research and development of these two proteins utilizing Protalix’s expression system; and A collaboration agreement with Procognia (Israel), Ltd. covering two biopharmaceuticals, under which Procognia would supply Teva services and access to its proprietary glycoanalysis technology.
During 2006, work on the transdermal hGH Teva/Transpharma joint project continued. Transdermal hGH is based on a proprietary transdermal technology licensed by Teva from Transpharma Medical, Ltd. under a 2004 agreement. This product is intended to provide both children and adults with an alternative to the injected therapy.
PROPRIETARY PRODUCTS
The company's proprietary research and development pipeline is focused mainly in three specialty areas: neurological disorders, autoimmune diseases and oncology.
Multiple Sclerosis
Copaxone: Copaxone, the company’s major product and is a multiple sclerosis (MS) therapy. Copaxone, which is indicated for the reduction of relapse rate in patients with relapsing-remitting MS, is a new class of modifying therapy with a dual mode of action that offers MS patients a different treatment concept. To further explore the efficacy of a new higher dose of Copaxone, at 40mg/day, a Phase III study entitled FORTE has been initiated to confirm the results from a completed Phase II study
As of December 31, 2006, Copaxone had been approved for marketing in 48 countries worldwide, including the United States, Canada, Israel, 22 European Union countries, Switzerland, Australia, Russia, Mexico, Brazil and Argentina.
In North America, Copaxone is marketed by Teva and is distributed by Sanofi-Aventis. Teva manufactures the product and supplies it to Sanofi-Aventis. Teva actively markets and promotes the product in the United States and Canada, respectively, through a range of activities. Teva and Sanofi-Aventis have an additional collaborative agreement for the marketing of Copaxone in Europe and other markets. Under the terms of this agreement, Copaxone is co-promoted with Sanofi-Aventis in Germany, the United Kingdom, France, Spain, The Netherlands and Belgium and is marketed solely by Sanofi-Aventis in the rest of the European markets, Australia and New Zealand. The product is manufactured by Teva, and Sanofi-Aventis purchases it from Teva and sells and distributes it in Europe.
Oral Copaxone for MS: In March 2006, Teva and Lundbeck A/S decided not to continue the development of a simple oral formulation of glatiramer acetate (the active ingredient of Copaxone). New and potentially improved formulations are in pre-clinical development.
Laquinimod: In 2004, Teva signed an agreement with Active Biotech, a Sweden-based, publicly traded biotechnology company, to develop and commercialize laquinimod, an orally bioavailable immunomodulatory compound. A Phase II study was performed by Active Biotech. An additional Phase IIb trial was completed in 2006. Under the terms of the agreement, Teva acquired the rights to develop, register, manufacture and commercialize laquinimod worldwide, with the exception of the Nordic and Baltic countries, where Active Biotech would retain commercial rights.
Cladribine (Mylinax): Through its acquisition of Ivax, Teva is a party to an agreement with Serono S.A. for the development of a proprietary oral formulation of cladribine (Mylinax ) as a treatment for MS. In 2005, Serono initiated a 1,200 patient two-year double-blind placebo-controlled study in patients with relapsing forms of MS.
Parkinson’s Disease
Azilect (rasagiline mesylate): Azilect (rasagiline tablets) is the company’s second significant drug, indicated for the treatment of Parkinson’s disease, both as initial monotherapy in early stage of the disease and as an adjunct to levodopa in moderate to advanced stages of the disease. Azilect is a potent, second-generation, irreversible monoamine oxidase type B (MAO-B) inhibitor with neuroprotective activities demonstrated in various in vitro and in vivo studies.
Teva launched Azilect in its first market, Israel, in March 2005, followed by a rolling launch in various European countries, including the United Kingdom in June 2005 and Germany in July 2005. During July 2006, Azilect became available in the U.S. In September 2006, Azilect was approved in Canada. As of December 31, 2006, Azilect had been made available in 24 countries, including Spain, Sweden, Belgium, Greece, The Netherlands and Romania.
The development of Azilect is part of a strategic alliance with Lundbeck A/S, which includes the global co-development and marketing of Azilect, mainly in Europe, for the treatment of Parkinson’s disease. Under this agreement, Lundbeck and Teva jointly market the product in certain key European countries. Lundbeck would exclusively market Azilect in the remaining European countries and certain other overseas markets. In November 2005, Teva initiated a randomized, double-blind and placebo-controlled Phase IIIb clinical study to determine whether treatment with once-daily Azilect can modify the progression of Parkinson’s disease.
Other Projects
The company has other projects in various development stages (including both clinical and pre-clinical) in the areas of psoriasis, asthma, amyotrophic lateral sclerosis, oncology and lupus.
Autoimmune Diseases Pipeline – Lupus
Systemic lupus erythematosus (SLE) is characterized as a chronic, diffuse autoimmune disorder, with rheumatological and dermatological damage to various tissues and organs.
Edratide Acetate (TV-4710) is a synthetic peptide based on the complementary-determining region 1 (CDR1) of the 16/6Id human anti-DNA antibody. This may enable specific modulation of the autoimmune processes in lupus. A Phase II trial in SLE patients is on-going in 12 countries in North America, Latin America, the European Union and Israel.
Neurology Pipeline:
Rasagiline Mesylate for Alzheimer’s Disease: Rasagiline has shown beneficial activity in experimental models relevant to Alzheimer’s disease. An early Phase II study of rasagiline in mild-to-moderate Alzheimer’s disease patients has been completed. The global Phase II study, in which rasagiline is used as an adjunctive treatment in Alzheimer’s patients treated with Aricept is on-going.
Ladostigil tartrate (TV-3326) is a compound developed for the treatment of Alzheimer’s disease and other forms of dementia.
Glatiramer acetate (GA) for Amyotrophic Lateral Sclerosis (ALS): The active ingredient of Copaxone in a 40 mg/day dosage form is being developed for the treatment of ALS. During December 2006, Teva completed recruitment of 300 patients into a double-blind, placebo-controlled multicenter Phase II clinical study.
Talampanel for ALS: Through the acquisition of Ivax, Teva has acquired worldwide rights to develop and market talampanel for the treatment of neurological disorders. Talampanel is an orally active antagonist of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) neuronal excitatory glutamate receptor. Following inconclusive Phase II studies in epilepsy and based on trends from a Phase II study in ALS, Teva is proceeding with the development of talampanel for the latter indication, and a new Phase II study to be initiated in late 2007 or early 2008 is being planned.
Oncology Pipeline
Talampanel has shown anti-tumor activity against malignant gliomas both in slowing their growth and reducing their ability to invade surrounding brain tissues. A Phase II study is on-going in the U.S.
StemEx: In February 2005, Teva signed a joint venture agreement with Gamida Cell, an Israeli-based, private biotechnology company, to develop and commercialize StemEx. StemEx is a cellular therapeutic, derived from cord blood, for the treatment of hematological malignancies. A Phase I/II study was completed.
New Ventures
In addition to the direct sourcing of projects from the Israeli academic community, Teva has also made equity investments and entered into agreements with various start-up and early-stage ventures. Teva’s direct investments include investments in Gamida-Cell, Ltd., CureTech, Ltd. and TransPharma Medical, Ltd. Teva has also invested in such companies, such as Biomedical Investments (1997), Ltd., Clal Biotechnology Industries Ltd. and BiolineRx Ltd., which in turn invest in companies or technologies.
ACTIVE PHARMACEUTICAL INGREDIENTS (API)
In addition to its production and sale of pharmaceutical products, Teva manufactures and sells active pharmaceutical ingredients. Teva offers approximately 250 different APIs, using synthetic, semi-synthetic, fermentation and high-potent technologies for use in pharmaceuticals. The products are sold to formulators of pharmaceutical products mainly in the U. S. and Europe, but also in Asia and Latin America.
Teva’s acquisition of Sicor complemented Teva’s existing API capabilities with a portfolio of APIs for respiratory products, dermatological hormones, anti-inflammatories, oncolytics, immunosuppressants, muscle relaxants and custom-manufactured APIs for various proprietary drug manufacturers.
The acquisition of Ivax has provided Teva’s API division with an additional 30 APIs and access to new technologies, mainly plant extraction technology. Through Ivax, Teva’s API division obtained access to new markets, such as CEE and Latin America. The API business sells products to Teva’s finished pharmaceutical product businesses and to third parties in a market for APIs mainly intended for generic products.
Teva’s API division has developed and acquired an expertise in specialized technologies, such as fermentation processes, high potency and the production of peptide API. This expertise enabled the API division to support launches of pravastatin and simvastatin in the United States in 2006 and also enabled Teva to sell fermentation products, such as lovastatin, simvastatin, pravastatin and tobramycin. In addition, through the establishment of joint ventures, Teva is also supplying various peptides, such as desmopressin, calcitonin, octreotide and others to its customers.
Marketing and Sales
In North America, the API division has marketed its products through Teva’s subsidiary Plantex USA. Majority of Plantex USA’s customers are generic dosage form manufacturers located in the U.S. and Canada. In Europe, Teva’s subsidiary Plantex Chemicals BV is responsible for marketing to European customers. The API division’s primary customers in Europe are generic pharmaceutical companies. In Asia, Latin America, Australia and New Zealand, Teva sells APIs through either local subsidiaries or local distributors. The company has established a subsidiary in Japan.
ANIMAL HEALTH
Through its IVX Animal Health subsidiary, Teva manufactures and markets proprietary, as well as generic, veterinary pharmaceutical products under IVX Animal Health’s own brand and for sale under private labels. IVX Animal Health serves major companion and economic animal segments with both prescription and over-the-counter products, and is a supplier of generic pharmaceuticals for economic animals in the United States. IVX Animal Health’s areas of focus include antimicrobials, antiparasitics, antipruritics and antiseborrheics, grooming aids, nutraceuticals and otics.
Teva’s animal health operations are also conducted through its Israeli subsidiary, Abic Ltd., which researches, develops, manufactures and markets veterinary products, both in Israel and internationally, particularly in Southeast Asia, Africa, Latin America and Eastern Europe.
Competition
The company’s major product Copaxone competes with formulations of beta-interferons, such as Avonex, Betaseron, Rebif, and Tysabri. Its other product Azilect competes with the newer non-ergot dopamine agonists, such as Mirapex /Sifroland Requip, as well as with Neupro. In the moderate to advanced stage of the disease, in addition to the dopamine agonists, Azilect is also competing with Comtan, a COM-T inhibitor.
History
Teva Pharmaceutical Industries Limited was founded in 1901.
